Literature DB >> 3640710

Alternative processing of H-2Dd pre-mRNAs results in membrane expression of differentially phosphorylated protein products.

J McCluskey, L F Boyd, W L Maloy, J E Coligan, D H Margulies.   

Abstract

Two distinct mRNA species encoding the mouse major histocompatibility antigen H-2Dd have been identified in BALB/c spleen cells as well as in cultured cell lines expressing this cell surface glycoprotein. The alternate transcripts of H-2Dd arise from either removal or inclusion of exon VII (encoding I2) during pre-mRNA processing. The relative levels of each kind of H-2Dd transcript varied considerably between different cell types, and in all cells examined both forms of alloantigen were expressed on the cell membrane. Antigen derived from both types of transcript reacted with H-2Dd-specific monoclonal antibodies, whereas only protein lacking the 13 amino acids of I2 reacted with a specific antiserum raised against a predicted exon VI/VIII fusion peptide. Those H-2Dd proteins translated from full length, but not smaller, transcripts were phosphorylated in resting and phorbol myristate acetate-stimulated BALB/c spleen cells, suggesting that the major site of in vivo phosphorylation is within the highly conserved sequence encoded by exon VII. Thus alternative splicing of pre-mRNA transcripts is a mechanism which leads to membrane expression of two forms of H-2Dd, one of which lacks a major site of phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3640710      PMCID: PMC1167142          DOI: 10.1002/j.1460-2075.1986.tb04524.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  59 in total

1.  Quantitative film detection of 3H and 14C in polyacrylamide gels by fluorography.

Authors:  R A Laskey; A D Mills
Journal:  Eur J Biochem       Date:  1975-08-15

2.  Effective radioiodination by lactoperoxidase and solubilisation of cell-surface proteins of cultured murine T lymphoma cells.

Authors:  D Haustein
Journal:  J Immunol Methods       Date:  1975-04       Impact factor: 2.303

3.  Structure and expression of two porcine genomic clones encoding class I MHC antigens.

Authors:  M L Satz; L C Wang; D S Singer; S Rudikoff
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

4.  Establishment and characterization of BALB/c lymphoma lines with B cell properties.

Authors:  K J Kim; C Kanellopoulos-Langevin; R M Merwin; D H Sachs; R Asofsky
Journal:  J Immunol       Date:  1979-02       Impact factor: 5.422

5.  Two mRNAs can be produced from a single immunoglobulin mu gene by alternative RNA processing pathways.

Authors:  P Early; J Rogers; M Davis; K Calame; M Bond; R Wall; L Hood
Journal:  Cell       Date:  1980-06       Impact factor: 41.582

6.  Regulation of adenovirus-2 gene expression at the level of transcriptional termination and RNA processing.

Authors:  J R Nevins; M C Wilson
Journal:  Nature       Date:  1981-03-12       Impact factor: 49.962

7.  Phosphorylation in vivo and in vitro of human histocompatibility antigens (HLA-A and HLA-B) in the carboxy-terminal intracellular domain.

Authors:  J S Pober; B C Guild; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

8.  Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity.

Authors:  S Cohen; G Carpenter; L King
Journal:  J Biol Chem       Date:  1980-05-25       Impact factor: 5.157

9.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

10.  Mouse histocompatibility genes: structure and organisation of a Kd gene.

Authors:  S Kvist; L Roberts; B Dobberstein
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  19 in total

Review 1.  Pathways for antigen cross presentation.

Authors:  Pierre Guermonprez; Sebastian Amigorena
Journal:  Springer Semin Immunopathol       Date:  2004-12-03

2.  Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens.

Authors:  A Ishitani; D E Geraghty
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

3.  Class I major histocompatibility complex cDNA clones from sheep thymus: alternative splicing could make a long cytoplasmic tail.

Authors:  D Grossberger; W Hein; A Marcuz
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

4.  Biosynthesis, glycosylation, and partial N-terminal amino acid sequence of the T-cell-activating protein TAP.

Authors:  H Reiser; J Coligan; B Benacerraf; K L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

Review 5.  Multiple class I molecules generated from single genes by alternative splicing of pre-mRNAs.

Authors:  A M Lew; J McCluskey; W L Maloy; D H Margulies; J E Coligan
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

6.  Characterization of five distinct cDNA clones encoding for class I RT1 antigens.

Authors:  F Mauxion; J Sobczak; M Kress
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

7.  Analysis of D2d: a D-region class I gene.

Authors:  M L Hedley; S W Hunt; K A Brorson; J S Andris; L Hood; J Forman; P W Tucker
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

8.  Signals controlling alternative splicing of major histocompatibility complex H-2 class I pre-mRNA.

Authors:  D E Handy; J McCluskey; A M Lew; J E Coligan; D H Margulies
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

Review 9.  Comparison of the primary structure of class I molecules.

Authors:  W L Maloy
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

10.  A novel H-2K splice form: predictions for other alternative H-2 splicing events.

Authors:  J M Vogel; R Y Morse; R S Goodenow
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.